Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
Shinichi OkaVicki HolohanTakuma ShirasakaJun Yong ChoiYeon-Sook KimNadine ChamayParul PatelJoseph W PolliSusan L FordHerta CrauwelsLouise GarsideRonald D'AmicoChristine LathamRodica van Solingen-RisteaBryan BaughJean van WykPublished in: HIV medicine (2023)
CAB + RPV LA demonstrated high efficacy, with no participants having CVF, and an acceptable safety profile in Asian participants through week 96. These data support CAB + RPV LA as a complete regimen for the maintenance of HIV-1 virological suppression in Asian individuals.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv infected patients
- hiv positive
- human immunodeficiency virus
- hiv aids
- hepatitis c virus
- electronic health record
- hiv testing
- type diabetes
- randomized controlled trial
- skeletal muscle
- south africa
- case control
- men who have sex with men
- machine learning
- artificial intelligence
- weight loss